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It is globally accepted that natural products play a crucial role in drug discovery. In the last decade, 
the investigation of marine natural products has resulted in a remarkable number of compounds 
with promising biological activities. Marine natural products have been shown to display 
antibacterial, antifungal, anticancer, antiviral, antiparasitic, anti-inflammatory activity and several 
other pharmacological activities of benefit to humankind.  
In this project, an investigation of the anti-inflammatory and immunostimulatory activities of extracts 
from two Arctic marine invertebrate species; a bryozoan, Eucratea loricata, and a sea urchin, Echinus 
esculentus, is presented. Anti-inflammatory activity was analyzed by using the 
monocyte/macrophage cell lines: THP-1 (accurate monocytic leukemia) and U937 (leukemic 
monocyte lymphoma). Immunostimulatory activity was analyzed by using THP-1 cell line. Effects on 
cell culture were monitored as reduced NFκB reporter activity in transfected cell line, and as reduced 
or increased production of the cytokines TNF-α and IL-1β. 
Bioassay-guided fractionation of the extracts revealed the presence of anti-inflammatory activity in 
the Echinus esculentus extracts. The structure of the target compound was partly elucidated using 
high resolution mass spectrometry, mass spectrometric fragmentation, and nuclear magnetic 
resonance spectroscopy. 
In addition, this present project provides background information about natural product research 
and current anti-inflammatory investigations of marine invertebrate species. Furthermore, the 
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The MabCent-SFI is a Centre for Research-based Innovation on Marine Bioactives and Drug 
Discovery. In the MabCent-SFI program, Marbank collects and stores Arctic and sub-Arctic marine 
organisms for further taxonomy studies and extract production. Bioassay guided purification, 
screening and identification of bioactive compounds are performed by the analytical platform 
Marbio. By using high-throughput assays, Marbio screen for novel bioactivities against bacteria, 
viruses and tumors as well as antioxidant, anti-diabetics, immunostimulants and anti-inflammatory 
activities. 
In the period 2007-2011, MabCent has performed more than 260 000 screening events and identified 
several “hits”, and some of these hits may become valuable drug “leads”. In cooperation with four 
commercial partners, MabCent-SFI has identified and characterized the structure of over 40 bioactive 
molecules, and based on this MabCent has two patents [1]. 
 
 
1.2 Marine bioprospecting 
Throughout the ages, natural products have always been the mainstay of disease therapy, and are 
still considered to play an important role in modern medicine. Almost half of the drugs approved 
since 1994 are based on natural products. It is well known that plants, microorganisms, marine 
organisms, vertebrates and invertebrates are important sources where natural product medicines 
have derived from [2-5]. 
In the last 30 years, the interest in marine bioprospecting has increased among researchers in the 
whole world. The marine environment differs from land-based ecosystems and offers a great 
chemical diversity and high biochemical specificity. Relatively low octanol-water partition coefficient, 
more rotable bonds and stereogenic centres are some of the chemical properties of small-molecule 
natural products that make them favorable as lead structures for drugs discovery [6, 7]. Marine 
organisms are therefore considered as treasures that remain a relatively unexplored source for novel 
bioactive compounds that could eventually be developed into therapeutics. 
However, as a consequence of the complex molecular structures of natural products, pharmaceutical 
companies have lately shifted to using synthetic chemical libraries. Clinical trials for new natural 
therapeutic  products was reduced with 30 % between 2001-2008 [8]. In addition to structural 
complexity, drug discovery from natural products faces many other challenges, such as difficulty in 
collection process, limited sample quantity and problems associated with purification and 
identification of active agents. Once identified, the molecules are often complex which may be 
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difficult and expensive to produce synthetically. Besides, crude fractions of biological materials are 
not as amenable to high throughput screening (HTS) as libraries of pure synthetic compounds [6, 9]. 
Despite this decline, the utility of natural products as sources for novel structures in drug discovery, 
without a doubt, is still in progress. From around the 1940s to date, of the 175 small molecules 
related to cancer research, approximately 50 % are actually either natural products or natural 
product derivatives. The current success rate of drug discovery from the marine environment is 
approximately 1.7- to 3.3-fold better than the industry average [7, 9, 10].  
Currently, the Food and Drug Administration (FDA) in the United States have approved three marine-
derived drugs, namely Cytarabine (1) (Cytosar-U®, discovered in sponges), Vidarabine (2) (Vira-A®, 
discovered in sponges), and Ziconotide (3) (Prialt®, discovered in cone snails). The disease area for 
these drugs are cancer, antiviral and pain, respectively [11]. In 2007 the European Union approved a 
marine-derived anticancer drug, Trabectedin (4) (Yondelis®).  In addition, 13 marine-derived 
compounds are either in phase I, phase II or phase III clinical trials, and several hundred novel marine 
compounds are in the preclinical pharmaceutical pipeline [11, 12]. As mentioned, marine-derived 
drugs have shown anticancer and antiviral activities. However, it has also been discovered marine 
compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, 
antiprotozoal, and antituberculosis effects, in addition to a number of other pharmacological 
activities which is necessary in treatment and preventment of diseases [11-14].  
With several agents approved as drugs, and the rich pipeline of agents in clinical trial and preclinical 
evaluation, the marine environment has performed exceptionally well in yielding new drugs. This 
suggests that the value of natural products in new drug discovery will continue to be significant in the 












Inflammation is a defensive response triggered when the body is threatened by for example 
pathogens, damaged cells or irritants. These responses are essential for humans in combating 
infections and for promoting healing and restoration to normal function in the event of injury. 
Unfortunately, these defensive responses can occasionally go wrong, leading to different 
inflammatory diseases.  
Inflammatory diseases include rheumatoid arthritis, atherosclerosis, Alzheimer’s, asthma, psoriasis, 
multiple sclerosis, and inflammatory bowel diseases, and many of these inflammatory diseases are 
becoming common throughout the world [15, 16]. According to World Health Organization (WHO) 
estimates, about 235 million people suffer from asthma and it is the most common chronic disease 
among children. Approximately 0.3–1.0% of the general population is affected of rheumatoid 
arthritis. It has been estimated that rheumatoid arthritis affects approximately 1.5 million people in 
the United States and the prevalence in Norway is estimated to be about 0.5 %. Like other 
inflammatory diseases, asthma and rheumatic conditions continue to be a large and growing public 
health problem [17-19].  
The three major groups of drugs used in treatment of inflammatory diseases are corticosteroids, 
non-steroidal anti-inflammatory drugs (NSAIDs), and disease-modifying antirheumatoid drugs 
(DMARDs), which include biological agents. These drugs are widely used and are effective in treating 
many inflammatory diseases. Corticosteroids also play a major role in the therapy of organ 
transplantation because of their anti-inflammatory and immunosuppressive effects. Unfortunately, 
they are also associated with several serious side effects, while the biological agents are expensive in 
use. Corticosteroids are well known for causing Cushing’s syndrome, in addition to other adverse 
effects such as hyperglycemia, increased susceptibility to infection, psychiatric disturbances, etc. 
Long term use of NSAIDs causes gastrointestinal ulceration and bleeding and platelet dysfunction [16, 
20].  
Inflammation is a complex process involving a multifactorial network of chemical signals to mediate 
the action. The primary anti-inflammatory targets include cyclo-oxygenase (COX)-1 and 2 enzymes, 
cytokines such as tumor necrosis factor (TNF)-α and interleukins (IL-1β, IL-6), and transcription factor 
as nuclear factor (NF)-κB and several more. TNF-α and ILs have been identified to play a central role 
in the pathogenesis of many inflammation diseases, especially asthma and rheumatoid arthritis. TNF-
α and ILs are intercellular signal proteins released by immune cells, and have many functions in 
promotion and resolution of inflammation. The transcription factor NF-κB is a main regulator of the 
expression of several genes involved in the activation of inflammation. NF-κB has been described to 
have a major role in pathogenesis of inflammatory bowel diseases and also of rheumatic diseases. It 
is well established that the excessive production of pro-inflammatory mediators is implicated in 
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several inflammatory diseases. Therefore, inhibition of the overproduction of these mediators is a 
crucial, exciting target in treatment of these conditions [15, 16, 20]. 
 
 
1.4 Anti-inflammatory drug discovery 
It is now globally accepted that natural products play a dominant role in the discovery of leads for 
the development of drugs for treating human diseases. Thus, natural products offer great hope in the 
identification of bioactive compounds and their development into drugs for the treatment of 
inflammatory diseases.  
Cyclosporine (5) is a natural product which has been successfully developed as first-line 
immunosuppressive medicine in treatment of transplant rejection. This compound was discovered by 
accident in 1972 and isolated from the fungus Tolypocladium inflatum from Hardangervidda, 
Norway. Cyclosporine was approved for use in 1983 and has since been an important medication, 
apart from in transplants, in the treatment of inflammatory diseases like rheumatoid arthritis and 
psoriasis. The drug has numerous actions related to immunosuppressive activity, but the main action 
is a selective inhibitory effect on IL-2 and IL-4 gene transcription [16, 21]. This example highlights the 
significant role of natural products as a source of drug discovery. 
Recently, there have been identified numerous anti-inflammatory pharmacologically active 
compounds from marine organisms. These compounds have been purified from many different 
marine sources including sponges, molluscs, bryozoans, sea combs, algae, echinoderms, ascidians 
and bacteria[13, 15, 22-26]. The Red alga Gracilaria verrucosa have possessed anti-inflammatory 
activities by inhibition of lipopolysaccharide (LPS)-induced nitric oxide (NO) production, TNF-α and IL-
6 [27]. Earlier studies have suggested that lipid extract of the blue-green alga Nostoc commune 
repressed expression of pro-inflammatory mediators, such as TNF-α, COX-2, IL-6 and IL-1β, by 
inhibiting the activation of NF-κB pathway in RAW 264.7 macrophages [28]. Astaxanthin, the main 
carotenoid pigment found in the marine world of algae and aquatic animals, have shown anti-
inflammatory properties. Astaxanthin have exhibited anti-inflammatory activities by suppressing the 
NF-κB activation. It inhibited the production of pro-inflammatory mediators such as TNF-α and IL-1β 
[29]. Hymenialdisine alkaloids isolated from marine sponges, such as Acanthella aurantica and 
Stylissa massa, are considered as potential anti-inflammatory agents. Its anti-inflammatory 
properties achieved through interfering with NFκB, in addition to the ability to decrease the IL-8 and 
IL-1β production [30-32]. 
Several reviews have been published on natural anti-inflammatory compounds with other particular 
targets like COX-1 and -2, lipoxygenases (LOXs), nitric oxide (NO), phopholipases A2 (PLA2s) pathway 
etc. These pro-inflammatory mediators have also been considered as potential targets in anti-
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inflammatory drug discovery. Many new anti-inflammatory cembranolides have recently been 
identified from different soft coral Lobophytum. These cembranolides inhibited the expression of 
inducible nitric oxid synthase (iNOS) and COX-2 [13, 33, 34]. Several marine organisms, especially 
corals, snails and sponges, have shown to inhibit the enzymatic activity of PLA2 [15, 22]. Although 
these active compounds are not drugs per se, they have exhibited anti-inflammatory activity through 









1.5 Sea urchin 
 
Figure 1: Sea urchins, Echinus esculentus. Photo: © S-R. Birkely, MARBANK 
 
There are over 6000 species of the phylum Echinodermata, and the sea urchins are included in this 
phylum. The body of a sea urchin is spherical, hard-shelled and covered with movable spines. Their 
normal size is about 3-10 cm in diameter [35]. Sea urchins feed mainly on algae and encrusting 
animals. Along with four or five gonads, the digestive tract takes up most of the internal space of the 
sea urchin. The gonads of sea urchins are eaten in several places around the world, including the 
United Kingdom and Portugal. Sea urchins can be found all over the world in all oceans. 
Approximately 15 species of sea urchin have been detected along the Norwegian coast [36]. 
Currently, several publications have suggested that sea urchins are a rich source for bioactive 
compounds, and in 2008 the first antimicrobial peptides (AMPs) isolated from sea urchins were 
reported. These were Strongylocins 1 and 2, and were isolated from coelomocyte extracts of the 
green sea urchins, Strongylocentrotus droebachiensis. These sea urchins were collected off the coast 
of Tromsø, Norway, and displayed potent activities against Gram-positive and Gram-negative 
bacteria [37]. Similarly, two novel AMPs, named Centrocins 1 and 2, were presented by Li et al. in 
2010. These peptides were isolated and characterized from a coelomycyte extract of the same 
specie, and also showed potent antibacterial activity [38]. In a previous study, done by Haug et al., 
antibacterial activity was also detected in different body parts of the same species of sea urchins. The 
highest antibacterial activity was found in the shell and in the coelomocytes [39]. Sheean et al. have 
detected anti-inflammatory activity in extracts from gonadal tissue of the Australian purple sea 
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urchin Heliocidaris erythrogramma. The extracts have possessed different levels of anti-inflammatory 
activity by inhibition of COX-1 and 2 [40]. 
Even though further investigation is required, several studies have already suggested that sea urchins 





Figure 2: The picture shows a colony of Eucratea loricata. Photo: ©Robert Andre Johansen, MARBANK 
 
Bryozoans are small (<1 mm), aquatic and benthic invertebrates that live in colonies. These animals 
have also been called for living fossils; they have existed on earth for about 600 million years and 
have not changed appreciably over the last 300 million years [35, 36]. The bryozoan body consists of 
a polyp, protected by a gelatinous or calcareous box. Bryozoans are sessile filter-feeders and food is 
collected via a circle of ciliated tentacles [35]. Bryozoans are found in both freshwater and marine 
environments, but no biologically active compounds have been identified from freshwater 
bryozoans. There have been described more than 8000 species of bryozoans, thereof more than 400 
have been verified in Norwegian waters [35, 36]. Due to the diversity, complexity and the sessile 
nature of the colonies, the bryozoans have been regarded as a promising source for bioactive 
compounds. 
Approximately 200 different compounds from 32 species have already been identified, and it has 
been found compounds with potential commercial value in 14 of these species [41]. Bryostatin 1, 
amathaspiramides, alternamides and perfragilin are compounds from bryozoans that have shown 
cytotoxicity against human cancer cells [41-43]. Among the 13 agents of marine origin currently in 
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clinical trials, bryostatin 1 is in phase I. Other compounds from bryozoans, convolutamine H 27 and 
convolutindole A 33, have also shown an inhibitory effect on the development of the larval stage of 
Haemonchus contortus, a type of sheep parasites. This discovery has potential clinical use as the 
potency of these two compounds are greater than commercially available products [41].  
Recently, MabCent in cooperation with other universities has isolated four compounds from the 
Arctic bryozoan Tegella cf. spitzbergensis. The ent-eusynstyelamide B (6) and three new derivatives, 
eusynstyelamides D (7), E (8) and F (9), all four compounds have revealed antibacterial activities. In 
addition, eusynstyelamides D and E have also shown weak cytotoxic activity against the human 
melanoma A 2058 cell line [44]. 
Considering the great diversity of bioactive compounds found in relatively few species of the 
manifold bryozoan world, searching for pharmacologically active compounds from bryozoans appear 













1.7 Natural products drug discovery 
There are two main strategies for research in the area of natural products; older- and modern 
strategy [45]. In the older strategy, the chemistry of compounds is in focus and selection of natural 
sources is based mainly on ethnopharmacological information as well as traditional uses. Isolation 
and identification of compounds are performed before biological activity testing (primarily in vivo). 
The modern strategy, so-called bioactivity-guided isolation is, as the name indicates, more focused 
on bioactivity. Biological assays (mainly in vitro) are used to target the isolation of bioactive 
compounds. Selection of organisms is based on ethnopharmacological information and traditional 
use, but might also be randomly selected. In modern strategy natural marine sources are particularly 
utilized. 
In this project, the bioassay-guided isolation strategy was applied. Below is a short overview of the 
processes used in this project (fig. 3). The steps required for the preparation of the material prior to 
extraction includes collection, taxonomic determination and storage of the samples. 
There are various extraction methods available in the field of marine natural products drug 
discovery. The choice of extraction method depends on the nature of the source material as well as 
the aim of the isolation. Extraction is a process of obtaining one or more components from a solid 
material or withdrawal of a solute from a liquid to another liquid. Solid samples are usually cut into 
small pieces or ground into fine particles to facilitate solvent penetration. Stirring or shaking can be 
applied to increase the diffusion rate. In this project, the extraction aims at getting as many new 
compounds as possible to introduce them in further biological assays. Thus, a water extraction and 
an organic extraction were performed. The water extraction isolates hydrophilic compounds, while 
the organic extraction is used to isolate lipophilic substances (fig. 3; step 1). 
The crude extracts are complex mixture of compounds, and are therefore not suitable for instant 
bioactivity screening. Thus, the crude extracts need to be fractionated prior to bioactivity screening 
(fig. 3; step 2). There are several techniques available for fractionation of crude extracts. Here, HPLC 
and flash chromatography was applied. Fractionation is a procedure used to separate mixtures into 
fractions, which have compositions consistent with the gradient. HPLC is a high performance method 
using small particle media, suited to the purification of complex samples where high purity is 
required. Flash is a useful technique for rapid separation and offers a higher loading capacity than 
the preparative HPLC, but with a lower resolution. Consequently, samples purified on a flash 
chromatography system will more than often need a second purification step to obtain a pure 
compound. 
The HPLC and flash fractions were further investigated by biological assays to pinpoint possible active 
compound(s) (fig. 3; step 3). A bioassay can be defined as the use of a biological system to detect 
properties, e.g. antibacterial, anticancer, anti-inflammatory etc., of fractions under controlled 
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conditions. In this project, in vitro bioassays were carried out by two cell lines; THP-1 and U937, to 
identify anti-inflammatory and immunostimulatory properties. Fractions that were considered to be 
active in the primary screening were re-tested to eliminate the possibility of getting false positives. 
Once the bioactive fractions were identified after the secondary screening, further analysis was done 
by high-resolution mass spectrometry (HR-MS). This technique permits characterization of active 
compounds based on molecular weight and elemental composition. Subsequently, those compounds 
suspected to provide activity were identified, and the HR-MS data was used for a search query in 
different databases of natural products to ascertain whether the molecules are previously known, 
the so-called dereplication process (fig. 3; step 4). 
Further purification and isolation of active compounds was achieved by using preparative HPLC-MS 
(fig. 3; step 5). This technique allows the isolation of compounds based on their mass-to-charge (m/z) 
ratio. 
The next step was structure elucidation of the isolated compounds (fig. 3; step 6). There are different 
spectroscopic techniques for structure determination of natural products. In this project structure 
elucidation was carried out by using high resolution mass spectrometry, tandem mass spectrometry 
(MS/MS) and nuclear magnetic resonance spectroscopy (NMR). MS/MS gives information about 
fragmentation pattern. Electrospray ionization was used to produce ions from molecules. NMR 
spectrum provides information about the number of protons and carbons as well as presence of 
other elements such as nitrogen and bromide, and the binding orientation of these atoms. 
With data from HR-MS, MS/MS, and NMR, the molecular structure of active compounds might be 
determined with quite high reliability. 
In this project, the purified compound was further dissolved in DMSO and bioscreened in a dilution 




Figure 3: A general overview of the processes involved in natural products drug discovery. 
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1.8 The aim of thesis 
The aim of this project was to investigate extracts from a bryozoan, Eucratea loricata, and a sea 
urchin, Echinus esculentus for anti-inflammatory activities. If possible, the molecular structure of the 
active compounds would be determined using high resolution mass spectrometry, mass 




2 Material and methods 
2.1 Sampling and storage 
The bryozoan, Eucratea loricata, identification number M08004, was obtained in January 2007 
outside Bear Island (Bjørnøya) located in the western part of the Barents Sea. It was found at 30 m 
depth. The biomass sample was stored at -22 °C in the dark. 
 
The Sea urchin, Echinus esculentus, identification number M10027, was collected in May 2010, at 56 
m depth, outside Hammerfest, Bondøya in Finnmark. The organism was stored at -22 °C in the dark. 
Further, different body parts were extracted separately, and the extracts were stored at -22 °C in the 
dark. In this project, extracts M10027-1; gonad, and M10027-2; intestines, were examined. 
 
 
2.2 Extraction of Eucratea loricata 
Materials used: 
DCM (99.8 %, Merck, Darmstadt, Germany) 
MeOH (99.9 %, Sigma-Aldrich, St.Louis, MO, USA) 
MilliQ water (Millipore, Billerica, MA, USA) 
Centrifuge: Heraeus Multifuge 3 S-R (Hanau, Germany) 
Freeze-drier: Heto Power Dry PL9000 (Thermo Fisher Scientific, Waltman, MA, USA) 
A11 Basic grinder (IKA Works, Staufen, Germany) 
Rotary evaporator: Heidolph Laborata 4002 (Nürnberg, Germany) 
Scale: Mettler Toledo PB3002-S Fact (Greifensee, Switzerland) 
Whatman filter paper 125 Ø (no. 3) (Springfield Mill, England) 
 
Preparation of the samples: 
The material was cut into approximately 1 cm3 pieces while still frozen, then transferred to Pyrex 
dishes, covered with perforated aluminum foil and freeze dried for 2 days. 
 
Aqueous extraction: 
The freeze-dried material was pulverized and transferred to tara 1 L Duran bottles. MilliQ water was 
added, approximately ten times the dry weight of the material (a total of 1.7 L water), and shaken 
until the suspension got a slurry consistency. The suspension was extracted at 5 °C for 20 hours. 
Extraction was performed at 5 °C to minimize the risk of bacterial decomposition of the compounds 
of interest and to maintain the sample stability. 
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The suspension was centrifuged at 3400 g, 5 °C for 30 minutes. The water supernatant was collected 
and the pellet re-extracted with MilliQ water (a total of 1.0 L) for 30 minutes. After centrifugation, 
the supernatant was collected and stored at 5 °C for 20 hours. The pellet was transferred to Pyrex 
dishes and stored at -22 °C for the organic extraction. 
The supernatant was transferred to 1 L round flasks (approximately 200 mL per flask) and stored at -
22 °C. The flasks were turned every 30 minutes during freezing to get as large surface area of the ice 
as possible. This was done to reduce the time of freeze-drying. The supernatant was then freeze-
dried for 3 days, before the material was grinded with mortar and pistil, transferred to 50 mL 
centrifuge tubes and stored at -22 °C in the dark. 
 
Organic extraction: 
The freeze-dried pellet was grinded and collected in tara 1 L Duran bottles, (about 30-40 g powder 
per bottle). The material was then extracted with the solvent mixture DCM-MeOH, (1:1, v/v). 
Approximately 10x of the materials weight of the extractive solvent was added (1.4 L), until the 
suspension got a slurry consistency. The suspension was extracted at 5 °C for 20 hours before it was 
vacuum filtrated with Whatman no. 3 filters. The extraction was repeated one more time with DCM-
MeOH solvent (0.6 L), for 30 minutes and then filtrated.  In total 2.0 L of DCM-MeOH was used in the 
organic extraction. 
The filtrate was then concentrated to 10-20 mL using a rotavapor before transferred to 13 mm test 
tubes and stored at -22 °C in the dark. 
 
 
2.3 Preparation of the extracts before HPLC fractionating 
Material used: 
ACN (99.9 %, Merck) 
EtOH (99.9 %, Sigma-Aldrich) 
Hexane (97.0 %, Sigma-Aldrich) 
MilliQ water (Millipore) 
Centrifuge: Biofuge Pico (Heraeus) 
Centrifuge: Heraeus Multifuge 3 S-R 
Millex GS filter 0.22 µm (Millipore) 
Minishaker: VWR international, Radnor 
Rotary evaporator: Heidolph Laborata 4002 




Preparation of the aqueous extract: 
200 mg of the extract was transferred to 13 mL centrifuge tubes and 2 mL MilliQ water was added. 
The tubes were placed horizontally on the shaking apparatus, and shaken for 90 minutes at 160 
rpm/minute. Afterwards, 1 mL of the mixture was mixed with 4 mL 96% EtOH, the mixture shaken on 
the minishaker and then stored at -22 °C for 20 hours. 
Next day the mixture was placed in room temperature (approximately 23 °C) for 5 minutes before 
shaken on the minishaker, and centrifuged at 3400 g, at 5 °C for 30 minutes. The supernatant was 
collected and evaporated with a rotavapor down to less than 2.0 mL. The volume was then 
distributed to two eppendorf tubes and filled up to 1 mL with MilliQ water, before centrifuged on the 
centrifuge Biofuge Pico at 16200 g, 5 °C, for 30 minutes. The supernatant was filtrated with 0.22 µm 
Millex GC filter. The filtrate was collected in two 12 mm HPLC tubes, and filled up with MilliQ water 
to 1 mL. 
 
Preparation of the organic extract: 
Approximately 300 mg of the extract was dissolved in 3 mL hexane and shaken 4 times on the 
minishaker with a 1 minute break between the shaking. 3 mL 90 % ACN was added and mixed on the 
minishaker before the sample was centrifuged at 20 g for 3 minutes. The hexane phase was removed 
and extracted once more with 3 mL 90 % ACN. The ACN phases were concentrated with a rotavapor 
until there was less than 1 mL left before the sample was stored at 5 °C for 20 hours. 
Next day, the sample was transferred to a 1 mL centrifuge tube and the volume adjusted to 1 mL 
using 90 % ACN. The sample was centrifuged at 16200 g, at 5 °C, for 30 minutes. The supernatant was 
transferred to a 12 mm HPLC tube, and the volume adjusted to 1 mL with 90 % ACN. 
 
 
2.4 HPLC fractionation of the aqueous and organic extracts 
Material used: 
Column: xTerra prep RP18, 10*300 mm, particle size 10 µm (Waters, Milford, MA, USA) 
Degasser: Waters prep 
Detector: Waters 2996 Photodiode Array 
Fraction collector: Waters 2767 sample manger 
Injector: Waters 600 controller 
Pump: Waters 515 HPLC 
RVT4104 Refrigerated Trap (Thermo Fisher Scientific) 
SC250 Express SpeedVac Concentrator (Thermo Fisher Scientific) 
Software: Waters MassLynx 4.1; Waters Openlynx 3.5; Waters fractionLynx 3.5 
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Mobile phase A: MilliQ water (Millipore) with 0.1 % formic acid (98.0 %, Merck) 
Mobile phase B: ACN (99.9 %, Merck) with 0.1 % formic acid (Merck) 
 
900 µl of the sample was injected. A linear gradient was selected and the gradient used for the 
aqueous extract and organic extracts can be found in table 5 and 6, respectively. In total, 40 fractions 
were collected for each sample. Each of the 40 fractions was distributed in 4 deep well plates. The 
plates were vacuum centrifuged for 3 hours to remove organic solvents and then freeze-dried for 24 
hours to remove the remaining water. 
 
Table 1: HPLC gradient used for the aqueous extract fractionation 
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
(Initial) 6 95 5 
2 6 95 5 
30 6 50 50 
40 6 5 95 
 
Table 2: HPLC gradient used for the organic extracts fractionation  
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
(Initial) 6 80 20 
2 6 80 20 
30 6 0 100 
40 6 0 100 
 
 
2.5 Flash chromatography of the organic extracts 
Material used: 
Acetone (99.8 %, Sigma-Aldrich) 
MeOH (99.9 %, Sigma-Aldrich) 
MilliQ water (Millipore) 
Flash system: Biotage SP4 (Uppsala, Sweden) 
Flash stationary phase: Diaion HP20SS, particle size 75-150 µm (Sigma-Aldrich) 
SC250 Express SpeedVac Concentrator (Thermo) 
RVT4104 Refrigerated Trap (Thermo) 
 
Preparation of the organic extracts before flash fractionation: 
2 g extract was dissolved in hexane (40 mL/g), and subsequently liquid-liquid extracted twice with 40 
mL 90 % MeOH. The MeOH phases were collected and concentrated to approximately 2 mL. The 
sample was then divided in two 13 mm centrifuge tubes, and 1 g diaion HP20SS was added to each 




The samples were added to the top of the column with stationary phase (approximately 6 g), and a 
stepwise gradient was selected and used (table 3). The fractionations were operated with a flowrate 
of 12mL/min and gave 24 mL in each fraction. This resulted in 27 fractions of each sample. Further, 
each fraction was concentrated to approximately 1 mL, and transferred to tara 13 mm tubes, before 
vacuum centrifuged to dryness. The dry mass of each flash fraction was then weighed. 
 
Table 3: Gradient used for the organic extracts flash fractionation 
Time (min) % water % MeOH % Acetone Fraction number 
0-6 95 5  1-3 
6-12 75 25  4-6 
12-18 50 50  7-9 
18-24 25 75  10-12 
24-36  100  13-18 
36-40  50 50 19-20 
40-54   100 21-27 
 
 
2.6 Dissolving HPLC and flash fractions for bioactivities screening 
Material used: 
DMSO (99.5 %, Sigma-Aldrich) 
FBS (Biochrom) 
Gensumycin (Biochrom) 
Hygromycin B (Sigma-Aldrich) 
L-glutamine (Sigma-Aldrich, G7513) 
MilliQ water (Millipore) 
Penicillin/Streptomycin (Sigma-Aldrich, P4458) 
RPMI 1640 (Biochrom, FG1385) 
Shaking apparatus: Edmund Bühler GmbH SM 30 
 
Dissolving HPLC fractions: 
Assay media for THP-1: RPMI-1640 with 10 µg/mL Gensumycin 
Assay media for U937: 49 mL RPMI-1640, 1 mL penicillin/streptomycin, 74 µL hygromycin B, 1 mL FBS 
and 500 µL L-glutamine 
Aqueous fractions: dissolved with 750 µL assay media and shaken for 3 hours. 
Organic fractions: dissolved with 7.5 µL DMSO and shaken for 2.5 hours, subsequently, 750 µl assay 




Dissolving flash fractions: 
Each flash fraction was dissolved in DMSO to give a concentration of 40 mg/mL. The samples were 
then shaken for 30 minutes, before 25 µL of each fraction was transferred to a deep well plate, and 
filled up to 1 mL with MilliQ water to give a concentration 1 mg/mL. 
 
 
2.7 Thawing and splitting of U937 and THP-1 cells 
Material used: 
Centrifuge: Heraeus Multifuge 3 S-R (Hanau, Germany) 
FBS (Biochrom) 
Gensumycin 10mg/mL (Biochrom) 
Hygromycin B (Sigma-Aldrich) 
Incubator, 37 °C, 5 % CO2 
L-glutamine 200 µM (Sigma-Aldrich) 
Penicillin/Streptomycin (Sigma-Aldrich) 
RPMI-1640 (Biochrom) 
Sodium pyruvat 100 µM (Biochrom) 
 
Table 4: The composition of growth media and assay media in U937 and THP-1 cell lines.  
Cell line U937 THP-1 
Growth media 45 mL RPMI-1640, 1 mL penicillin/streptomycin,  
75 µL hygromycin B, 500 µL L-glutamine, 5 mL FBS 
50 mL RPMI-1640, 50 µL gensumycin,  
10 nM sodium pyruvat, 5 mL FBS 
Assay media 49 mL RPMI-1640, 1 mL penicillin/streptomycin,  
74 µL hygromycin B, 500 µL L-glutamine, 1 mL FBS 
RPMI-1640 with 10 µg/mL 
Gensumycin 
 
A sterile environment must be kept when working with the cells. This was done by aseptic technique 
and all equipment and reagents must be sterile before use (e.g. by autoclaved or washed with 70 % 
ethanol). Especially for the THP-1 cell line, media must be endotoxin free and all equipments have to 
be pyrogen free. 
 
Thawing cells from the nitrogen tank: 
A cryotube with cells was taken out from a nitrogen tank and immediately placed into a 37 °C water 
bath for thawing. The thawed cells were then transferred to a 50 mL centrifuge tube and 10 mL of 
pre-warmed growth media (37 °C) was added dropwise, slowly at the beginning and then faster, over 
a period of two minutes. Afterwards the cell suspension was centrifuged at 200 g for 7 minutes. The 
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supernatant was removed and 10 mL growth media was added. The cell suspension was transferred 
to a culture flask and incubated at 37 °C, with 5 % CO2. 
 
Cell splitting: 
Before splitting, the cells were inspected in microscope to check for cell density, if the cells appeared 
to be normal and confluent, then they were split. 
The cell culture was transferred to a 50 mL centrifuge tube and centrifuged at 200 g for 7 minutes. 
The supernatant was then poured out and the cell pellet was resuspended in new pre-warmed 
growth media. 
For U937: 10 µL cell suspensions were transferred to an eppendorf tube and 90 µL growth media was 
added, subsequently 10 µL cell dilution was transferred to a counting chamber for cell counting in a 
light microscope. The U937 cells were split on Monday and Wednesday 1:3 and Friday 1:5 in order to 
maintain the cell density between 0.1 x 106 and 2.0 x 106 cells/mL. 
For THP-1: 0.5 mL cell suspensions were transferred to a falcon tube and 0.5 mL trypan blue was 
added to count how many cells that were alive. After approximately 1 minute, 10 µL of the mix was 
transferred to a counting chamber for cell counting. The THP-1 cells were split twice a week with a 
cell density of approximately 2-3 x 105 cells/mL. 
 
 
2.8 Anti-inflammatory assay with U937 cell lines 
Material used: 
DMSO (99.5 %, Sigma-Aldrich) 
EnVision plate reader (Perkin Elmer) 
FBS (Biochrom) 
LPS 055:B5 (Sigma-Aldrich, L2880) 
One-Glo Luciferase assay buffer (Promega, E605) 
Assay media (table 4) 
Growth media (table 4) 
Negative control: assay media with 0.1 % DMSO 
Positive control: assay media with 1 µg/mL LPS 
 
On the experiment day, approximately 40 000 cells/well were seeded (8 x 105 cells/mL) in 50 µL assay 
media. The plates were stored at 37 °C, with 5 % CO2 for 3 hours. After incubation, the cells were 
inspected in microscope to check that they were alive and evenly distributed to all the wells, before 
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25 µL HPLC or 5 µL flash fraction and negative control were added (an overview of the complete 
process is shown in figure 4, while the plate setup is shown in figure 5). 
After 30 minutes incubation, assay media with 1 µg/mL LPS (positive control) was added to every 
well except the negative control wells. The plates were incubated over night at 37 °C, with 5 % CO2. 
Next day, 30 µL OneGlo-substrate was added to every well. The plates were then shaken at 400 rpm 
for 3-5 minutes in the dark.  
The plates were analyzed by monitoring NFκB activity in the cells by measuring relative light units 
(RLU) using an EnVision plate reader. Percentage activity was calculated by using negative controls 
and positive controls, which were included within every plate.  
MabCent have set different cut-off values for active and inactive fractions. Fractions were defined as 
active when NFκB activity was <50 %, questionable when fractions showed 50-75 % activity and 
inactive if NFκB activity was >75 %, compared to the LPS-treated cells. 
Active fractions were then identified and subsequently retested in a dilution series. The secondary 
screening was performed in the same manner as the primary screening, but with difference in plate 
setup and fraction concentration. Figure 6 and 7 show plate setup for HPLC and Flash fractions, 
respectively. HPLC fractions were tested undiluted, diluted 1:2 and 1:4. Flash fractions were tested at 
the concentrations 50, 25, 10 and 1 µg/mL. All fractions were tested in duplicates. 
 
 




 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  17 18 19 20 21 22 23 24 P P  
C  17 18 19 20 21 22 23 24 P P  
D  9 10 11 12 13 14 14 16 P P  
E  9 10 11 12 13 14 14 16 N  N  
F  1 2 3 4 5 6 7 8 N  N  
G  1 2 3 4 5 6 7 8 N  N  
H             
Figure 5: Placement of fractions (1-24) in a microtiter plate in primary anti-inflammatory screening with U937 cell line. P: 
positive control, N: negative control. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  A(u) A(u) C(u) C(u) E(u) E(u) G(u) G(u) P P  
C  A(1:2) A(1:2) C(1:2) C(1:2) E(1:2) E(1:2) G(1:2) G(1:2) P P  
D  A(1:4) A(1:4) C(1:4) C(1:4) E(1:4) E(1:4) G(1:4) G(1:4) P P  
E  B(u) B(u) D(u) D(u) F(u) F(u) H(u) H(u) N  N  
F  B(1:2) B(1:2) D(1:2) D(1:2) F(1:2) F(1:2) H(1:2) H(1:2) N  N  
G  B(1:4) B(1:4) D(1:4) D(1:4) F(1:4) F(1:4) H(1:4) H(1:4) N  N  
H             
Figure 6: Placement of HPLC fractions in a microtiter plate in secondary anti-inflammatory screening with U937 cell line. P: 
positive control, N: negative control, u: undiluted, diluted 1:2 and 1:4. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B  A50 A25 A10 A1 D50 D25 D10 D1 P P  
C  A50 A25 A10 A1 D50 D25 D10 D1 P P  
D  B50 B25 B10 B1 E50 E25 E10 E1 P P  
E  B50 B25 B10 B1 E50 E25 E10 E1 N  N  
F  C50 C25 C10 C1 F50 F25 F10 F1 N  N  
G  C50 C25 C10 C1 F50 F25 F10 F1 N  N  
H             
Figure 7: Placement of Flash fractions (with concentration: 50, 25, 10 and 1 µg/mL) in a microtiter plate in secondary anti-
inflammatory screening with U937 cell line. P: positive control, N: negative control.  
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2.9  Anti-inflammatory and immunostimulatory assay with THP-1 cell lines 
Material used: 
Anti-Human IL-1β Purified (eBioscience) 
Anti-Human TNF-α Purified (eBioscience) 
Biotin Anti-Human IL-1β (eBioscience) 
Biotin Anti-Human TNF-α (eBioscience) 
BSA (Sigma-Aldrich) 
Diethanolamine (99.0 %, Sigma-Aldrich) 
Extravidin alkaline phosphatase (Sigma-Aldrich) 
LPS 1 mg/mL (Sigma-Aldrich) 
MgCl2 (VWR) 
NaCl (VWR) 
Nunc Maxisorp 96F-well ELISA plate (VWR) 
Dulbecco’s PBS (Invitrogen) 
PMA, stock solution 1 mg/mL (Sigma-Aldrich)  
pNPP substrate (Sigma-Aldrich) 
Recombinant human IL-1β (Biolegend) 
Recombinant human TNF-α (Biolegend) 
Tris (Sigma-Aldrich) 
Tween-20 (VWR) 
ELx405 plate washer (Bio-tek) 
DTX 880 plate reader (Beckman Coulter) 
 
An overview of the entire procedure (preparation and ELISA assay) is given in figure 8. 
 
Preparation before ELISA: 
Day 1: A cell suspension with a concentration of 106 cells/mL was made, followed by the addition of 
50ng/mL PMA to make the monocytes differentiated to macrophages. 100 µL cell suspensions was 
transferred to each well in a 96-wells microtiter plate, and incubated at 37 °C, with 5 % CO2 for 48 
hours.  
Day 3: The cells were inspected in microscope to confirm that the monocytes had differentiated to 
macrophages and that cells were evenly distributed in every well. Then the old media was removed, 
the cells were washed with PBS (90 µL/well), and new growth media was added. The plates were 
incubated at 37 °C, with 5 % CO2 for 24 hours. 
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Day 4: The cell density was checked before the old growth media was removed, and new growth 
media was added, (90 µL/well). Following this 10 µL of the HPLC fraction was added. All fractions 
were tested in duplicates. 
Immunostimulatory assay: 10 µL of 50 ng/mL LPS solution was added to positive controls. The plates 
were incubated at 37 °C, with 5 % CO2 for 6 hours, and then kept at -80 °C until ELISA. 
Anti-inflammatory assay: the plates were incubated at 37 °C, with 5 % CO2 for 1 hour before 10 µL of 
50 ng/mL LPS solution was added to every well except the cell controls (negative controls). The plates 
were incubated at 37 °C, with 5 % CO2 for 6 hours, and afterwards stored at -80 °C until ELISA. 
 
Reagent preparation before ELISA: 
(All reagents were prepared immediately prior to use) 
TBS: 1.21 g Tris and 8.8 g NaCl per liter MilliQ water, pH 7.4 
Anti-Human antibodies solution:  the antibodies were diluted in 10 nM TBS to give a concentration of 
2 µg/mL 
Wash buffer: TBS with 0.05 % Tween-20 
Blocking buffer: TBS with 2 % BSA, pH 7.4 
Assay diluents: TBS with 1 % BSA, pH 7.4 
Biotin Anti-Human IL-1β solution: Anti-Human IL-1β biotin dilutes in the assay diluents to give a 
concentration of 0.5 µg/mL 
Biotin Anti-Human TNF- α solution: Anti-Human TNF- α biotin dilutes in the assay diluents to give a 
concentration of 3 µg/mL 
Extravidin alkaline phosphatase solution: Extravidin alkaline phosphatase dilutes 1:10000 in the assay 
diluents  
Diethanolamine buffer: 100 mg MgCl2 and 97 mL diethanolamine per liter MilliQ water, pH 9.8 
pNPP substrate solution: 1 mg/mL pNPP substrate in 1 M diethanolamine 
 
One day prior to running ELISA, Nunc Maxisorp 96F-well ELISA plates were coated with 100 µL 
antibody solution of “Anti-Human TNF-α Purified” (for TNF- α ELISA) or “Anti-Human IL-1β Purified” 






The sample plates were taken out from the freezer for thawing, while the pre-coated plates were 
washed with Wash buffer by using “Wash ELISA” program (300 µL Wash buffer/well, wash 4 times) in 
the ELx405 plate washer (all subsequent washes were performed similarly). Following this, 200 µL 
blocking buffer was added to all wells, and the plates were incubated at room temperature for 1 
hour while shaking. The plates were washed before assay diluents were added, subsequently, 
samples or standards were added. The total volume in each well should be 100 µL. See figure 9 for 
plate setup. 
For TNF- α ELISA: samples containing LPS were diluted 1:10 while samples without LPS were diluted 
1:2. A serial dilution of the 1000 pg/mL top standard was performed within each plate. Thus, the 
human TNF- α standard concentrations were 500, 250, 125, 62.5, 31.3, 15.6 pg/mL. Assay diluents 
served as the zero standard (0 pg/mL). In addition, cell controls and LPS controls (positive controls) 
were also included within every plate.  
For IL-1β ELISA:  samples containing LPS were diluted 1:4, samples without LPS were diluted 1:2. 
Similarly, a serial standard dilution of human IL-1β was also prepared as previously described in TNF- 
α ELISA. Cell controls and LPS controls were also included within the plates. 
The plates were then incubated at room temperature for 2 hours while shaking. Afterwards, the 
plates were washed by “Wash ELISA” program before 100 µL Anti-Human TNF- α Biotin solution (for 
TNF- α ELISA) and Anti-Human IL-1β Biotin solution (for IL-1β ELISA) was added to all wells. The plates 
were shaken at room temperature for 1 hour followed by washing and addition of 100 µL Extravidin-
alkaline phosphatase solution to all wells. The plates were incubated at room temperature for 30 
minutes with shaking before they were washed by “Soak wash ELISA” program (300 µL Wash 
buffer/well, soaking for 30 seconds per wash, wash 5 times). Next, 100 µL pNPP substrate solution 
was added to all wells, and the plates were incubated at room temperature for 45 minutes. 
Subsequently, the absorbance at 405 nm was determined for each well by using DTX 880 plate 
reader. The amount of TNF- α (for TNF- α ELISA) and IL-1β (for IL-1β ELISA) was calculated by using 
negative and positive controls which were included within each plate and expressed as percent. 
In the MabCent anti-inflammatory screening program with THP-1 cells, fractions with >50 % 
inhibition compared to LPS-treated cells were defined as active.  Fractions displaying 40-50 % 
inhibition were considered to be questionable, while those showing <40 % inhibition were inactive.  
In immunostimulatory screening, fractions possessing >10 % stimulation compared to LPS-treated 
cells were identified as immunostimulatory fractions. Fractions showing <5 % stimulation were 
defined as inactive, and questionable if displaying 5-10 % stimulation.  
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Active fractions were identified and retested in a dilution series. Secondary screening follows almost 
the same method as primary screening. However, the test concentrations used in this case were 




Figure 8: Overview of the anti-inflammatory and immunostimulatory assay TNF-α/IL-1β with THP-1 cell lines 
 
 1 2 3 4 5 6 7 8 9 10 11 12 














B 2 2 6 6 10 10 14 14 18 18 controls 
C 3 3 7 7 11 11 15 15 19 19 LPS 
D 4 4 8 8 12 12 16 16 20 20 controls 
E 21 21 25 25 29 29 33 33 37 37 Cell 
F 22 22 26 26 30 30 34 34 38 38 controls 
G 23 23 27 27 31 31 35 35 39 39 LPS 
H 24 24 28 28 32 32 36 36 40 40 control 
Figure 9: Placement of fractions in a 96-well ELISA plate in primary anti-inflammatory screening with THP-1 cell line. 
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2.10 Dereplication of the active HPLC fraction from the organic extracts of 
Echinus esculentus 
Based on the primary and secondary screening, HPLC fraction 27 from the organic extract M10027-1-
L01, and HPLC fraction 27 from the organic extract M10027-2-L01 were identified as active. 
Unfortunately, the amount of the crude organic extract M10027-2-L01 would not be enough to carry 
through isolation and the other following processes. Therefore HPLC fraction number 27 was not 
further investigated. However, HPLC fraction 27 of the organic extract M10027-1-L01 was analyzed 
by using ToF-MS to identify compound(s) that caused the observed anti-inflammatory activity. The 
analysis was carried out in both positive and negative electrospray mode. 
 
Material used: 
Waters Acquity UPLC 
Column: Acquity UPLC® BEH C18, 2.1*50 mm, particle size 1.7 µm 
MS: Waters LCT Premier 
Software MassLynx 4.1 
Mobile phase A: 0.1 % formic acid (Merck formic acid pro analyse) in MilliQ water 
Mobile phase B: 0.1 % formic acid (Merck formic acid pro analyse) in ACN (Merck ACN (99.9 %) HPLC 
grade) 
Standard ESI+/- conditions and UPLC gradient used for ToF-MS are listed in table 5 and 6, 
respectively. 
  




Table 6: The UPLC linear gradient used to analyze the accurate mass of the active compound 
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
(Initial) 0.35 80 20 
3.5 0.35 0 100 
5.0 0.35 0 100 
 
  
Polarity ES + ES - 
Capillary 2.60 kV 2.90 kV 











Cone gas flow 5 L/h 5 L/h 
Desolvation gas flow 500 L/h 650 L/h 
Syringe pump flow 5 µL/min 5 µL/min 
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In addition to the HPLC fraction 27, which displayed activity, the inactive HPLC fractions 25, 26 and 28 
were also analyzed. From these ToF-MS data, based on the chromatograms and spectra, a compound 
with m/z 568.3 was detected in the active fraction, and not in the inactive fractions. Consequently, 
this compound, with m/z 568.3, was surmised to cause the anti-inflammatory activity in cell 




2.11 Purification of the target compound from the organic extracts of Echinus 
esculentus 
Material used: 
ACN (99.9 %, Sigma-Aldrich) 
Formic acid (98.0 %, Merck) 
Hexane (97.0 %, Sigma-Aldrich) 
MeOH (99.9 %, Sigma-Aldrich) 
Rotary evaporator: Heidolph Laborata 4002 
HPLC-MS equipments (see section 2.4) 
SC250 Express SpeedVac Concentrator (Thermo) 
 
Preparation of the crude organic extract before purification: 
The active fraction was extracted and purified from the crude organic extract of M10027-1-L01. 3.0 g 
crude extract was extracted twice with 50 mL of 90 % (v/v) ACN and 50 mL hexane. The ACN phase 
was collected and concentrated to approximately 3 mL using a rotavapor. 
 
Purification of the active fraction: 
Isolation of the active compound was carried out by using the same HPLC-MS equipment, software 
and mobile phases as described in section 2.4. A X-Select CSH prep Fluoro-Phenyl 5 µm 10*250 mm 
column (Waters). The injection volume was set to 200 µL and the HPLC-MS was programmed to 
collect the compound with a mass-to-charge ratio of 568.3. The gradient used for purification of this 





Table 7: The mobile phase gradient used for purification of the target fraction 
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
(Initial) 6 56 44 
20 6 54 46 
21 6 0 100 
25 6 0 100 
 
Estimation of the purity of the isolated compound: 
Fractions containing m/z 568.3 from HPLC-MS purification were collected and concentrated down to 
1 mL by using speedVac. Furthermore, the sample was dissolved in 50 % (v/v) ACN and analyzed by 
UPLC-ToF-MS to estimate the purity of the isolated compound. The analysis was made in both 
positive and negative electrospray mode. The conditions used in ToF-MS are mentioned in table 5 
and the used gradient can be seen in table 8. Mobile phase A: MilliQ water with 0.1 % formic acid 
(98.0 %, Merck). Mobile phase B: ACN (99.9 %, Merck) with 0.1 % formic acid (Merck). 
 
Table 8: UPLC gradient using in UPLC-ToF-MS 
Time (min) Flow (mL/min) Mobile phase A (%) Mobile phase B (%) 
(Initial) 0.35 90 10 
10 0.35 0 100 
12 0.35 0 100 
 
 
2.12 Structure elucidation of the target compound 
The structure of the active compound was determined using NMR and tandem quadrupole MS/MS. 
 
Structure elucidation by using NMR: 
An Agilent Inova 600 MHz NMR spectrometer equipped with an inverse detection HCN cryprobe was 
used in the NMR analysis. 1.4 mg of the active compound was dissolved in 500 µL methanol-d4 and 
DMSO-d6 respectively. For both solvents, 1D 1H NMR, COSY, HSQC and HMBC were recorded using 
WET solvent suppression on the residual solvent peaks as well as the water peaks, gradient selection 
and adiabatic pulses where applicable. All NMR data was acquired at 298 K. 
 
Structure elucidation by using tandem quadrupole MS/MS: 
A Waters Xevo TQ-MS was applied for MS analysis of the purified compound. Nitrogen (from 
generator, Peak Scientific, Glasgow, UK) was used as cone gas and desolvation gas, and Argon 4.0 
(Aga, Oslo, Norway) was used as collision gas. The sample was infused directly into the MS with the 
built-in syringe pump. Cone voltage was optimized in order to get the highest intensity of the 
protonated molecular ion, and the collision energy was optimized during the infusion to produce an 
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2.13 Testing of the anti-inflammatory activity of the target compound 
0.8 mg of the isolated compound was dissolved in 16 µL DMSO (99.8 %, Sigma-Aldrich) and 24 µL 
MilliQ water to achieve a stock solution with a concentration of 20 mg/mL.  A dilution series was 
prepared from this stock solution in the concentrations 750, 500, 250, 100, 50, and 25 µg/mL. In the 
microtiterplate the target compound was diluted by a factor of 10. In this experiment it was taken 
into account that the THP-1 cells, based on previous experiences, tolerated only up to approximately 
0.1 % DMSO. In the presence of higher concentration of DMSO, the viability of THP-1 cell may be 
affected, consequently false positive might be brought about. 
The anti-inflammatory assay was performed as described in section 2.9. In addition to cell controls 
and LPS controls (positive controls) which were included within the plate, DMSO cell controls and 
DMSO LPS controls were also included. The DMSO concentration in the cell controls and the LPS 
controls was 0.15 %. This was done to make sure that DMSO did not cause the activity. All fractions 




3.1 Extraction yield of Eucratea loricata and Echinus esculentus 
The biomass wet weight of Eucratea loricata (M08004) was 1728.4 g, and after freeze-drying the 
biomass weight was 291.3 g. The biomass weight used for the aqueous extraction was 291.3 g, and 
the extraction yield 51.4 g. The material weight used for the organic extraction was 227.4 g, and the 
extraction yield 27.4 g. 
The wet-weight of Echinus esculentus gonad (M10027-1) was 1038.0 g and the dry-weight was 150.7 
g. This dry-weight of material was used for the aqueous extraction and yielded 54.1 g extract. The 
material weight used for the organic extraction was 80.1 g, and the extraction yield 33.1 g. 
The wet-weight of intestines of Echinus esculentus (M10027-2) was 1000.0 g and dry-weight was 
116.2 g. The weight used for aqueous extraction was 116.2 g and the yield 28.2 g. 78.5 g material was 
used for organic extraction, and this yielded 6.3 g. 
 
 
3.2 HPLC fractionation of Eucratea loricata and Echinus esculentus 
The aqueous and organic extracts were fractionated separately. The UV-chromatograms were 
obtained with wavelengths between 200-600 nm, and positive and negative electrospray data were 
acquired over an m/z range of 150-1500. 
As the UV-chromatogram shows in figure 10, most of the components of the aqueous extract of 
Eucratea loricata (M08004-0-W01) eluted between 2.5-7.0 minutes. In this interval, four larger peaks 
were detected at 2.76 (the injection peak), 3.95, 5.03 and 6.58 minutes. In the next 33 minutes a 
smaller peak appears at 10.56 but other than that nothing remarkable was registered. 
For the organic extract of Eucratea loricata (M08004-0-L01), most of the compounds were detected 
between the retention times of 8-24 minutes (fig. 11), with an injection peak which eluted at 2.55 
minutes. The UV-chromatogram shows many small and indistinct peaks. Both the UV- and the ion 
chromatograms of the organic extracts indicated that no components eluted after 25 minutes. 
The UV-chromatogram of the organic extract Echinus esculentus (M10027-1-L01) shows the injection 
peak at about 2.53 minutes (fig. 12). As the ion chromatograms reveals, the rest of components were 
detected at a retention time of 15-25 minutes. In this interval, several large and distinct peaks were 
observed.   
Most of the compounds from the organic extract of Echinus esculentus (M10027-2-L01) eluted 
between 10-25 minutes (fig. 13) and during this retention time, several distinct peaks were detected 




Figure 10: UV- and MS chromatograms of M08004-0-W01. A) UV-chromatogram at absorbance 200-600 nm, and B) 
negative and C) positive electrospray in the m/z range 150-1500. All the peaks are annotated with retention time (top) and 
UV-absorbance or m/z (bottom). 
 
 
Figure 11: UV- and MS chromatograms of M08004-0-L01. A) UV-chromatogram at absorbance 200-600 nm, and B) negative 
and C) positive electrospray in the m/z range 150-1500. All the peaks are annotated with retention time (top) and UV-




Figure 12: UV- and MS chromatograms of M10027-1-L01. A) UV-chromatogram at absorbance 200-600 nm, and B) negative 
and C) positive electrospray in the m/z range 150-1500. All the peaks are annotated with retention time (top) and UV-
absorbance or m/z (bottom). 
 
 
Figure 13: UV- and MS chromatograms of M10027-2-L01. A) UV-chromatogram at absorbance 200-600 nm, and B) negative 
and C) positive electrospray in the m/z range 150-1500. All the peaks are annotated with retention time (top) and UV-
absorbance or m/z (bottom). 
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3.3 Flash fractionation of the organic extracts 
All three organic crude extracts; M08004-0-L01, M10027-1-L01 and M10027-2-L01, were fractioned 
by flash chromatography. As it shows in table 9, all the three samples contained a high amount of 
compounds that eluted in the first fraction. Fraction numbers 13-16 contained a relatively high 
amount of extract compared to fractions 2-12 and 17-27. Sample M10027-1-L01, fraction number 7, 
differed from the rest in that it contained as much as 170 mg of the extract. 
 
Table 9: List over the weight of the extract of different samples yield after flash fractionation. 
 M08004-0-L01 M10027-1-L01 M10027-2-L01 
Fraction number Weight of the extract (mg) Weight of the extract (mg) Weight of the extract (mg) 
1 119.1 55.2 108.2 
2 68.1 4.1 6.2 
3 6.3 2.1 5.7 
4 4.6 1.4 3.5 
5 5.9 2.1 9.8 
6 2.9 1.8 5.8 
7 4 170.5 8.6 
8 7.4 4.4 26.5 
9 3 1.7 6 
10 2.4 39.8 4.1 
11 7.4 17.7 34.5 
12 6.5 2.1 3.5 
13 50.5 3.3 4 
14 149.3 142 151.9 
15 40.7 53 79.6 
16 16.5 32.4 23.7 
17 10.2 15.9 13 
18 6.7 8.1 8.6 
19 8.3 5.1 6.8 
20 17.6 7.8 7.6 
21 5.2 0.7 1.4 
22 5.2 3.4 2.6 
23 2 1.4 1.3 
24 1.5 1.3 1.3 
25 1.5 1.3 1.6 
26 1 1.2 1.1 





3.4 Anti-inflammatory and immunostimulatory bioscreening 
As described in section 2.8 and 2.9, MabCent have defined different cut-off values for active and 
inactive fractions. A short overview is listed in table 10. 
  
Table 10: Cut-off value for NFκB, IL-1β and TNF-α in anti-inflammatory screening (AFI), and for IL-1β and TNF-α in 
immunostimulatory screening (IS) 
Cell line Active Questionable Inactive 
NFκB in U937, AIF screening < 50 % activity 50-75% activity >75% activity 
IL-1β, TNF-α in THP-1, AIF screening >50 % inhibition 40-50 % inhibition <40 % inhibition 
IL-1β, TNF-α in THP-1, IS screening >10 % stimulation 5-10 % stimulation <5 % stimulation 
 
 
3.4.1 Anti-inflammatory screening of the aqueous extract of Eucratea loricata 
As it shows in figure 14, no HPLC fractions of the aqueous extract of Eucratea loricata reduced the 
NFκB reporter activity. 
Fractions 39 and 40 (fig. 15) are shown to have a weak anti-inflammatory activity, with an inhibitory 
effect on IL- production slightly over 50 % compared to LPS-treated cells. However, these fractions 
displayed no inhibitory activity on TNF-α production. Nevertheless, fractions 39 and 40 were retested 
for both IL-1β and TNF-α, but no inhibitory activity was observed (figure not shown). 
 
Figure 14: Primary anti-inflammatory screening of 40 different HPLC fractions from the aqueous extracts of Eucratea 
loricata (M08004-0-W01). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 






















Figure 15: Primary anti-inflammatory screening of 40 different HPLC fractions from the aqueous extracts of Eucratea 
loricata (M08004-0-W01). Each column represents the percent of IL-1β (blue) or TNF-α (red) production by the THP-1 cells 
after 7 hours of exposure to the HPLC fractions. 
 
 
3.4.2 Immunostimulatory screening of the aqueous extract of Eucratea loricata 
The aqueous extracts of Eucratea loricata did not exert any immunostimulatory effect in the TNF-α 
assay (fig. 16). In the IL-1β assay, fraction number 5 possessed the highest immunostimulatory 
activity with only 6 % stimulation. The activity was considered as questionable, but this was not 
further investigated. 
 
Figure 16: Primary immunostimulatory screening of 40 different HPLC fractions from the aqueous extracts of Eucratea 
loricata (M08004-0-W01). Each column represents the percent of IL-1β (blue) or TNF-α (red) production by the THP-1 cells 
















































3.4.3 Anti-inflammatory screening of the organic extract of Eucratea loricata 
The HPLC fractions of the organic extract of Eucratea loricata revealed anti-inflammatory activity in 
NFκB, TNF-α and IL-1β screening. Fractions 19-31 and 33 reduced the NFκB activity with more than 
50 % compared to LPS-treated cells (fig. 17). These fractions were identified as active and were 
retested. In the retesting (results shown in figure 18), fractions 22-28, 30 and 33 retained the anti-
inflammatory activity at undiluted concentration, but no anti-inflammatory activity was observed 
when diluted 1:2 and 1:4. 
 
Figure 17: Primary anti-inflammatory screening of 40 different HPLC fractions from the organic extracts of Eucratea loricata 
(M08004-0-L01). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 
exposure to the HPLC fractions. *Activity exceeds 240 % activity. 
 
 
Figure 18: Secondary anti-inflammatory screening of the active HPLC fractions from the organic extracts of Eucratea loricata 
(M08004-0-L01). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 










































As is shows in figure 19, fraction 25 displayed a weak inhibitory effect on IL-1 β production in THP-1 
cells, while fraction 33 revealed an inhibitory effect on TNF-α production. Nevertheless, these two 
fractions (25 and 33) were retested for both IL-1β and TNF-α but no inhibitory activity was observed 
neither at undiluted nor diluted concentrations (figure not shown). 
 
Figure 19: Primary anti-inflammatory screening of 40 different HPLC fractions from the organic extracts of Eucratea loricata 
(M08004-0-L01). Each column represents the percent of IL-1β (blue) or TNF-α (red) production by the THP-1 cells after 7 
hours of exposure to the HPLC fractions. 
 
In addition to the screening of the HPLC fractions of Eucratea loricata, screening of the organic flash 
fractions of this organism was also conducted. At the concentration of 50 µg/mL, the flash fractions 
10-12 of the organic extract of Eucratea loricata displayed anti-inflammatory activity in the NFκB 
assay in the U937 cell lines (fig. 20). These three fractions were retested in a dilution series (fig. 21). 
Fractions 11 and 12 still kept the anti-inflammatory activity at 50 µg/mL, and fraction 12 also at 25 
µg/mL, but the anti-inflammatory activity disappeared at further dilution. 
  
Figure 20: Primary anti-inflammatory screening of 27 different flash fractions from the organic extracts of Eucratea loricata 
(M08004-0-L03). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 












































Figure 21: Secondary anti-inflammatory screening of the active flash fractions from the extracts of Eucratea loricata 
(M08004-0-L03). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 
exposure to the flash fractions. *Activity exceeds 240 % activity. 
 
 
3.4.4 Immunostimulatory screening of the organic extract of Eucratea loricata 
As figure 22 shows, the organic extracts of Eucratea loricata displayed immunostimulatory effect in 
both IL-1β and TNF-α screening. The fractions 1, 13, 15-17, 19-24, 28 and 29 produced more than 10 
% of IL-1β compared to LPS-treated cells. These fractions were considered as active, especially 
fraction 17, 19, and 29 with a stimulatory effect of 147 %, 55 % and 53 % in IL-1β screening, 
respectively. Fractions 17, 21, 28 and 29 were also considered as active in the TNF-α screening. There 
is a higher probability of finding active compounds in those fractions showing activity in both IL-1β 
and TNF-α screening. Based on this, fractions 17, 21, 28 and 29 were retested.  
The results from the secondary screening revealed that only fraction 29, at undiluted concentration, 
displayed stimulatory effect slightly above 10 % compared to LPS-treated cells in IL-1β screening. The 
rest did not show any remarkable stimulatory effect at any concentrations in both IL-1β and TNF-α 
screening (figure not shown).  
 
Figure 22: Primary immunostimulatory screening of 40 different HPLC fractions from the organic extracts of Eucratea 
loricata (M08004-0-L01). Each column represents the percent of IL-1β (blue) or TNF-α (red) production by the THP-1 cells 
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3.4.5 Anti-inflammatory screening of the Echinus esculentus gonad extract 
The HPLC fractions of the organic extract, Echinus esculentus (M10027-1-L01), exhibit anti-
inflammatory activity on U937 cell lines (fig. 23). In this case fraction 27 possessed strong anti-
inflammatory activity. The same fraction also displayed activity in both IL-1β and TNF-α screening 
(fig. 24). Since fraction 27 was shown to be potent in NFκB, IL-1β and TNF-α assays, there is an 
increased likelihood of finding active compounds and therefore it was retested. 
 
Figure 23: Primary anti-inflammatory screening of 40 different HPLC fractions from the organic extracts Echinus esculentus 
(M10027-1-L01). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 
exposure to the HPLC fractions. *Activity exceeds 240 % activity. 
 
 
Figure 24: Primary anti-inflammatory screening of 40 different HPLC fractions from the organic extracts of Echinus 
esculentus (M10027-1-L01). Each column represents the percent of IL-1β (blue) or TNF-α (red) production by the THP-1 cells 












































The result from the retesting of fraction 27 with U937 revealed no activity (figure not shown). In TNF-
α retesting, the inhibitory effect was not high enough to be considered active (fig. 26). The undiluted 
concentration of fraction 27 retained the anti-inflammatory activity in IL-1 β screening, but this effect 
was lost in further dilution (fig. 25). Nevertheless, fraction 27 was a candidate for further 
investigation.  
 In THP-1 cells, the inhibitory effect of fraction 6 is questionable with a value slightly below 50 % in IL-
1β screening, and 57 % in TNF-α screening (fig. 25 and 26). This fraction was retested, but no anti-
inflammatory activity was observed.  
 
Figure 25: Secondary anti-inflammatory screening of the active HPLC fractions from the extracts of Echinus esculentus 
(M10027-1-L01). Each column represents the percent of IL-1β production by the THP-1 cells after 7 hours of exposure to the 
HPLC fractions (undiluted, diluted 1:2 and 1:4). 
 
 
Figure 26: Secondary anti-inflammatory screening of the active HPLC fractions from the extracts of Echinus esculentus 
(M10027-1-L01). Each column represents the percent of TNF-α production by the THP-1 cells after 7 hours of exposure to 


















































In addition to the screening of the HPLC fractions of the Echinus esculentus gonad (M10027-1-L01), 
the flash fractions of this sample were also screened against NFκB activity in U937. At 50 µg/mL, the 
flash fractions 8, 9, and 11-14 were considered to be active (fig. 27), but in retesting, the anti-
inflammatory activity was not observed in any of these fractions (fig. 28). 
 
Figure 27: Primary anti-inflammatory screening of 27 different flash fractions from the organic extracts of Echinus 
esculentus (M10027-1-L03). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 
hours of exposure to the flash fractions. 
 
 
Figure 28: Secondary anti-inflammatory screening of the active flash fractions from the extracts of Echinus esculentus 
(M10027-1-L03). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 
exposure to the flash fractions. 
 
 
3.4.6 Immunostimulatory screening of the Echinus esculentus gonad extract 
In the immunostimulatory screening of the Echinus esculentus gonad extract, no HPLC fractions were 
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3.4.7 Anti-inflammatory screening of the Echinus esculentus intestines extract 
HPLC fractions 26 and 27 from Echinus esculentus intestines were shown to have anti-inflammatory 
activity in NFκB assay in the U937 (fig. 29). In retesting, as figure 30 shows, fraction 26 kept the 
activity at undiluted concentration, but the activity diminished at further dilution. For fraction 27, 
activity was observed in both undiluted and dilute concentration 1:2. However at 1:4 dilution, the 
anti-inflammatory activity became very weak. 
 
Figure 29: Primary anti-inflammatory screening of 40 different HPLC fractions from the organic extracts of Echinus 
esculentus (M10027-2-L01). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 
hours of exposure to the HPLC fractions. *Activity exceeds 240 % activity. 
 
 
Figure 30: Secondary anti-inflammatory screening of the active HPLC fractions from the extracts of Echinus esculentus 
(M10027-2-L01). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 
exposure to the HPLC fractions (undiluted, diluted 1:2 and 1:4). 
 
In the THP-1 cells assay (fig. 31), fraction 27 was identified to be active in IL-1β screening, while 
fraction 7, 8, 12, 16, 21, 27 and 28 were active in TNF-α screening. Since the results from both IL-1β 
and TNF-α screening were consistent with each other in that the fraction 27 revealed anti-
inflammatory activity, only this fraction was retested. In both IL-1β and TNF-α screening this fraction 









































of activity (fig. 32 and 33). However, as figure 33 shows, the fraction 27 possessed a dose-response 
relationship in the TNF-α assay. 
 
Figure 31: Primary anti-inflammatory screening of 40 different HPLC fractions from the organic extracts of Echinus 
esculentus (M10027-2-L01). Each column represents the percent of IL-1β (blue) or TNF-α (red) production by the THP-1 cells 
after 7 hours of exposure to the HPLC fractions. *Activity (%) exceeds 90 % activity. 
 
 
Figure 32: Secondary anti-inflammatory screening of the active HPLC fractions from the extracts of Echinus esculentus 
(M10027-2-L01). Each column represents the percent of IL-1β production by the THP-1 cells after 7 hours of exposure to the 
HPLC fractions (undiluted, diluted 1:2 and 1:4). 
 
 
Figure 33: Secondary anti-inflammatory screening of the active HPLC fractions from the extracts of Echinus esculentus 
(M10027-2-L01). Each column represents the percent of TNF-α production by the THP-1 cells after 7 hours of exposure to 



































































In addition to the screening of the HPLC fractions of the Eucratea loricata intestines (M10027-2-L01), 
screening of the organic flash fractions (50 µg/mL) of this organ was also conducted. The flash 
fractions 8-17 of this extract displayed anti-inflammatory activity in the NFκB assay in the U937 cell 
lines (fig. 34). These fractions were identified to be active and were retested. As figure 35 shows, only 
fractions 16 and 17 retained activity at 50 µg/mL, and fraction 16 also at 25µg/mL, but the activity 
declined in further dilution. However, as the columns show, both fractions revealed a dose-response 
relationship. Fraction 15 also showed a dose-response relationship, but even at the highest 
concentration, the activity was over the cut-off value. The other fractions did not exhibit significant 
activity at any concentration. 
 
Figure 34: Primary anti-inflammatory screening of 27 different flash fractions from the organic extracts of Echinus 
esculentus (M10027-2-L03). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 
hours of exposure to the flash fractions. *Activity exceeds 240 % activity. 
 
 
Figure 35: Secondary anti-inflammatory screening of the active flash fractions from the extracts of Echinus esculentus 
(M10027-2-L03). Each column represents the percent of the LPS-induced NFκB activity in the U937 cells after 24 hours of 
exposure to the flash fractions. 
 
 
3.4.8 Immunostimulatory screening of the Echinus esculentus intestines extract 
HPLC fractions of the Echinus esculentus intestines did not exhibit any stimulatory activity in the TNF-
α screening. In the IL-1β screening, a weak stimulatory activity was observed in some of the fractions, 
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3.5 Dereplication of the active HPLC fraction from the Echinus esculentus gonad 
extract 
After the primary and secondary screening, the bioactivity data showed that the HPLC fraction 27 of 
the Echinus esculentus intestines was active. Since the results from all three NFκB, IL-1β, and TNF-α 
screening were consistent with each other, this fraction was considered to contain the compound(s) 
that caused the observed anti-inflammatory activity. The fraction revealed a dose-response 
relationship in all three different assays (fig. 30, 32 and 33). This fraction was therefore a candidate 
for further investigation. Unfortunately, as mentioned in section 2.10, the amount of the crude 
organic extract M10027-2-L01 was too minuscule to any further purification and characterization. 
However, the bioactivity data revealed that the HPLC fraction 27 of the Echinus esculentus gonad also 
possessed anti-inflammatory activity in all three primary NFκB, IL-1β, and TNF-α screening. A weak 
dose-response relationship was also detected in the secondary screening of TNF-α.  
Both fractions 27 from the M10027-1-L01 and the M10027-2-L01 extracts were further analyzed by 
ToF-MS, and the data indicated that these fractions contained the same compounds as the ToF-MS 
chromatograms of these fractions were quite similar. Hence, the HPLC fraction 27 of the Echinus 
esculentus gonad was further investigated. 
To identify the compound(s) that possibly caused the observed anti-inflammatory activity in the 
bioactivity screening, the active fraction 27 and the inactive fractions 25, 26 and 28, were analyzed 
by UPLC-ToF-MS. Possible active compound(s) were determined by the comparison of the 
chromatograms and the spectra of the active fraction and the inactive fractions. The compound with 
m/z 568.3 was detected in the active fraction but not in the inactive fractions, therefore the molecule 
with mass 567.3417 amu was selected as a target for isolation. 
The dereplication of the target compound in fraction 27 from the organic extract M10027-1-L01, as is 
shown in figure 36, gave the protonated mass of the compound to be 568.3417 amu. From the 
isotope pattern and the accurate mass, the MS software calculated the elemental composition of the 
target compound to be C30H50NO7P (in ESI+ mode the compound will have one extra H), with a mass 
accuracy of -0.5 ppm and i-Fit value of 267.5 (fig. 36). The accurate mass and the elemental 
composition were also used for a search query in the database Dictionary of Marine Natural 









3.6 Purification of the target compound from the Echinus esculentus gonad extract 
An up-scaled purification of the target compound of the crude extract M10027-1-L01 was performed 
to provide sufficient material for structure elucidation and the studies of the biological mode of 
action. The purification of the target compound was achieved by using preparative HPLC coupled 
with fraction triggering ESI+ MS. Several gradients of mobile phases were tested to obtain an 
optimized gradient in order to improve isolation of the compound. The preparative HPLC-MS was set 
to collect the protonated mass 568.3 amu with a minimum intensity threshold (MIT) of 1 000 000. As 
seen in figure 37, the HPLC-MS separated the target compound, 568.3 amu (protonated mass), from 
the other compounds. The compound eluted after approximately 10 minutes with the selected 
gradient. A total of approximately 2.5 mL extract was injected, (13 injections), and the yield was 1.40 







Figure 37: Chromatogram of the target compound by using HPLC-ESI+ MS. The time is on the X-axis and the peak intensity is 
on the Y-axis. The purple section is where the protonated compound with mass 568.3 amu was collected from the flow 
from the HPLC column. All the peaks are annotated with retention time (top) and m/z (bottom). 
 
UPLC-ToF-MS of the purified compound from Echinus esculentus: 
To estimate the purity of the isolated compound it was analyzed by UPLC-ToF-MS in positive and 
negative mode. As seen in figure 38, the MS chromatograms indicated the successful purification of 
the target compound in the preparative HPLC-MS. From the ESI+ chromatogram (fig. 38, A), the 
compound with m/z 568.3164 [M+H]+ is by far the dominating signal indicating few impurities. Two 
smaller peaks were detected right before the compound eluted at 6.28 min. Similarly, the ESI- 
chromatogram (fig. 38, B) showing the dominating signal of the m/z 612.3312 [M+FA-H]- compound. 
A smaller peak was observed right before the compound eluted at 6.27 min, a smaller peak was also 
detected at 6.69 min.
 
Figure 38: UPLC-ToF-MS chromatogram of the purified compound. A) positive and B) negative electrospray in the m/z range 




3.7 Structure elucidation of the target compound 
The elemental composition of the isolated compound (C30H50NO7P) was established using ToF-MS 
during dereplication. In order to determine the actual structure of the compound it was analyzed by 
NMR and tandem quadrupole MS/MS. 
 
NMR of the purified compound from Echinus esculentus: 
In attempt to achieve a full structure elucidation, the purified compound was also analyzed by NMR 
spectroscopy, and 1D 1H NMR, COSY, HSQC and HMBC were recorded. 
As seen in figure 39, the 1H NMR spectrum showed resonances in the aliphatic region (1-2ppm), this 
has also been confirmed by the 2D COSY spectrum (fig. 40) and the HSQC+HMBC spectrum (fig. 41). 
Both spectra revealed a peak at around 0.6 ppm (peak w). There were no aromatic resonances in the 
spectrum (7-8 ppm).  
The HSQC spectroscopy for carbon-proton interactions revealed a hydroxyl group with hydrogen shift 
at around 3.3 and carbon shift at approximately 65 (fig. 41, peak E) and ether group with hydrogen 
shift at approximately 3.6 and carbon shift at around 67 (fig. 41, peak D). This was also observed in 
the 2D COSY spectrum (fig. 40, peak E and D). 
The HSQC+HMBC spectrum and the 2D COSY analysis for proton interactions of the sample displayed 
resonances in the trimethylamine region. As figure 41 shows, the trimethylamine group has 
hydrogen shift at around 3.1 (f1) and carbon shift at approximately 55 (f2). The carbon at 65 ppm 
was found to be bearing two hydrogen atoms (4.0 ppm) and one nitrogen atom (fig. 41, peak H). The 
carbon at 60 ppm was shown to be attached to two hydrogen atoms and a phosphate group (fig. 41, 
peak G).  
With the elemental composition (C30H50NO7P) calculated by MS software and the NMR results, it was 
suggested that the molecule structure consist of a phosphocholine group with unknown side 
chain(s).  
However, since the sample amount was too small and not pure enough to provide clear signals, 
identification of the structure with high reliability was challenging. Moreover, some signals were 











H NMR specter of the purified compound. The large peak at 1.25 ppm implied alkane chain, and the peaks at 




















Figure 40: 2D COSY specter of the purified compound. The peaks are signed according to the structure of the purified 
compound. The peak I at approximately 3.1 ppm (f2) implied the trimethylamine group, hydroxyl group revealed a shift at 





















Figure 41: HSQC+HMBC specter of the purified compound. The peaks are signed according to the structure of the purified 
compound. The trimethylamine group show hydrogen shift (f2) at approximately 3.1 (peak I) and carbon shift at 
approximately 51. Hydroxyl group revealed carbon shift at about 65 (peak E), and ether group with carbon shift at 
approximately 6.7 (peak D). Hydrogen shift (ppm) is on the x-axis (f2), and carbon shift (ppm) is on the y-axis. 
 
Tandem quadrupole MS/MS of the purified compound from Echinus esculentus: 
The information provided from the UPLC-ToF-MS and NMR analysis implied that the purified 
compound consist a phosphocholine group with an unknown side chain. To confirm the 
phosphocholine group presence in the compound, analysis by a tandem quadrupole MS/MS was 
performed. A positive ion daughter scan of the m/z 568.3 ([M+H]+) was performed. The daughter ion 
specter is seen in figure 42, and some of the most intense fragment ions are explained in figure 43 
(and also in figure 44). The phosphocholine fragment ion revealed the mass-to-charge ratio at 184. 
The fragment ion with m/z 551 is consistent with the mass of the molecule (568.3 amu) when it loses 
a hydroxyl group. However, some intense fragment ions could not be explained from the surmised 
phosphocholine molecular structure show in figure 43, especially the fragment ion m/z 301.12. As 
seen in figure 43, the fragment ion m/z 285 could be identified if the oxygen atom was assumed to 
be placed in the unidentified chain, but the intense fragment ion m/z 301 could not be explained. 
However, the fragment ion m/z 301 can be explained by the molecular structure suggested in figure 





Figure 42: ES+ MS/MS daughter ion scan specter of the purified compound at m/z 568.3. All the fragments are annotated 




Figure 43: Structure of phosphocholine showing the fragments with an unidentified side chain, which was presumed to 
contain an oxygen atom. 
 
 
Figure 44: Structure of phosphocholine showing the fragments with an unidentified side chain. The fragments shows here 




3.8 Testing of the anti-inflammatory activity of the target compound 
After dereplication, purification, isolation and structure elucidation of the target compound, it was 
retested to confirm the anti-inflammatory activity observed in the primary and secondary screening 
with THP-1 cells. As figure 45 shows, the target compound did not exert anti-inflammatory activity at 
any concentrations tested neither in the IL-1β nor the TNF-α screening. 
 
Figure 45: Anti-inflammatory screening of the target compound from the extracts of Echinus esculentus (M10027-1-L01). 
Each column represents the percent of IL-1β (blue) or TNF-α (red) production by the THP-1 cells after 7 hours of exposure to 
























4  Discussion 
Over the last years, the marine environment has provided a remarkable proportion of compounds 
with anti-inflammatory activities. The need for novel anti-inflammatory drugs is increasing due to 
issues concerning the serious side effects of the traditional anti-inflammatory drugs. The aim of this 
project has been to investigate for anti-inflammatory and immunostimulatory activities of extracts 
from two Arctic marine invertebrate species; a bryozoan, Eucratea loricata, and a sea urchin, Echinus 
esculentus. Further, an attempt to elucidate the structure of the purified compound was carried out. 
Although bioassay-guided fractionation has become a powerful tool in natural products drug 
discovery, cell-based assays of natural product extracts are complicated. One of the challenges is 
associated with the complexity of the biological system. The anti-inflammatory NFκB assay with U937 
cells is relying on a reporter gene, and due to signal amplification of cell-signaling cascades, reporter 
gene assays are very sensitive immune systems. Thus, all foreign substances that could not be 
recognized by the cells might trigger the cells to response. These non-specific interferences may also 
occur in THP-1 cells and trigger the production of IL-1β and TNF-α, or it may be as simple as the 
concentrations of the substances present in the extract are too high so that they interact 
nonspecifically with a receptor in the cells. In addition, unfortunately, natural products extracts are 
typically complex mixtures and the concentrations of different substances in crude extracts are 
unknown. 
Since the screening for compounds exerting anti-inflammatory or immunostimulatory activities was 
not always easy owing to the complexity of cellular interactions involved during an inflammatory 
response, the same fractions were tested against several targets. The data generated from various 
assays made it possible to compare whether the results were consistent with each other. If the same 
fractions revealed activities in at least two of three assays, the fractions was considered as a 
potential candidate for further investigation. By this way, it provided the opportunity to sort out, in 
an early stage, whether the observed anti-inflammatory was due to non-specific effects or specific 
anti-inflammatory effects. 
It was prepared an aqueous extract and an organic extract of the bryozoan. The screening results 
show that more anti-inflammatory activity was found in the HPLC organic fractions than in the HPLC 
aqueous fractions. There are many possible explanations for this. The most common problem 
associated with water extracts is bacterial and fungal growth and these microorganisms might 
degrade active components present in the extract. Moreover, water extracts normally contain ionic 
and polar substances, which are not cell membrane permeable and therefore unable to reach a 
potential cellular target. 
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Because no HPLC fractions of the aqueous extract reduced the NFκB reporter activity, moreover, only 
fractions 39 and 40 possessed weak activity (55% and 53%, respectively) in the IL- 1β assay but not in 
the TNF-α assay, the aqueous extract was not fractioned by flash chromatography. In addition, due 
to the experience obtained at MabCent, the organic solvent extracts are relatively enriched in 
smaller, moderately polar and non-polar molecules. These small molecules are the ones most likely 
to have drug-like properties, so it is believed that there is a greater likelihood of detecting biologically 
active substances in the organic extracts. The crude extracts from the organic extractions were 
therefore fractioned by both HPLC and flash chromatography. The dry weight of each fraction after 
flash fractionation (table 9) was dissolved in DMSO to give a concentration of 40mg/mL. In this 
manner, fractionation by flash chromatography provides the opportunity to have control over the 
test concentration as early as possible in the primary screening. 
Although 15 (fractions 19-31 and 33) of the 40 HPLC fractions of the bryozoan organic extract 
displayed anti-inflammatory activity in the primary NFκB screening, only fraction 25 showed a weak 
activity in the IL-1β testing, and only fraction 33 revealed activity in the TNF-α screening. The results 
from NFκB, IL-1β and TNF-α assays were not consistent with each other. In NFκB activity retesting, 
the anti-inflammatory activities in fractions 22-27, 30 and 33 were reproducible at undiluted 
concentration, but not at diluted concentrations. For fractions 25 and 33, the activity could neither 
be replicated in IL-1β or TNF-α assay. Similarly, the flash fractions 10, 11 and 12 displayed activity in 
NFκB assay, but in the retest, the activity could not be observed at dilute concentrations. This might 
be explained by the non-specific effects, the activity could be observed when there was high enough 
amount of substances present in the fractions, and once the fractions were diluted, the activity could 
not be detected. The same reason might also explain why the HPLC fractions 17, 21, 28 and 29 
exerted the immunostimulatory activity in the primary IL-1β or TNF-α assay, but not in the retest. In 
addition, because of the high sensitivity of the assays, any foreign substances might provoke the cells 
to respond.  
The HPLC fraction 6 of the gonad extract from the Echinus esculentus (M10027-1-L01) revealed anti-
inflammatory activities in both IL-1β and TNF-α assay. And the HPLC fraction 27 displayed activity in 
all three assays. In retesting of the fractions 6 and 27, only fraction 27 retained the activity in the IL-
1β assay at undiluted concentration. The flash fractions 8, 9 and 11-14 from the same extract showed 
anti-inflammatory activity in NFκB assay, but the activity could not be replicated in the retest. As 
discussed above, the anti-inflammatory activity observed in the primary testing might owe to the 
non-specific response in the cells. 
In the screening of Echinus esculentus intestinal (M10027-2-L01), the HPLC fraction 27 exerted strong 
anti-inflammatory activities in all three NFκB, IL-1β and TNF-α assays. In NFκB retesting, the fraction 
retained the activity at undiluted and diluted concentration 1:2. In both IL-1β and TNF-α retesting, 
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the fraction possessed activity only at undiluted concentration. However, both NFκB and TNF-α 
assays gave a good dose-response relationship. Similarly, the flash fractions 16 and 17 also showed a 
dose-response relationship in NFκB retesting. This might indicate that the observed anti-
inflammatory activities were truly caused by the specific responses from cells since the activities 
declined corresponded to the concentrations of the fractions. 
It was suspected that the HPLC fraction 27 and the flash fractions 16 and 17 might consists of similar 
substances, since the polarity of the mobile phases at the time the HPLC fraction 27 eluted was 
similar to the mobile phases polarity at the time flash fractions 16 and 17 eluted. This could be 
confirmed by using ToF-MS to analyze these fractions. Comparison of ToF-MS chromatograms and 
spectra of these fractions might reveal whether the same substances were present in these fractions. 
Nevertheless, this was not prioritized due to the insufficiency of crude M10027-2-L01 extract for 
further investigation. 
Bioactivity data was used in order to guide the identification of the target compound for structure 
elucidation. The results from ToF-MS analysis of the HPLC fraction 27 from both gonad and intestinal 
extracts of the Echinus esculentus, indicated that both fractions most likely consisted of the same 
substances. Therefore, it was decided to dereplicate and isolate compounds from fraction 27 from 
the gonad extract.  
During the dereplication, the compounds m/z 341.2, 345.1 and 568.3 were discovered in fraction 27 
but not in the nearby inactive fractions. In addition, since the concentration of these compounds was 
correlated with the activity exerted by fraction 27, these compounds, with m/z 341.2, 345.1, and 
568.3, were suspected to be the compounds that might cause the observed anti-inflammatory 
activity. However, after repeated isolation attempts of m/z 341.2 and 345.1, these two compounds 
could not be detected in ToF-MS even though isolation by the preparative HPLC-MS seemed to be 
successful. Earlier it has been shown that this is not entirely uncommon. Natural products are well 
known for their chemical complexity, and marine extracts may contain extremely labile compounds. 
Decomposition of these compounds may occur at any step during the purification process. Heat, 
light, air and pH are among other factors that may lead to the degradation of compounds. Materials 
used for separation may also activate some reactions. 
Nevertheless, isolation of the compound with m/z 568.3 was successful and structure elucidation of 
this compound was carried out using MS and NMR. From the ToF-MS data, the empirical formula of 
the compound was calculated to be C30H51NO7P. Analysis of the MS and NMR data indicated that the 
compound consisted of a phosphocholine group with an unknown side chain. Because of the splitting 
in the peak I on the 2D COSY and the HSQC+HMBC spectrum (fig. 40 and 41), as well as some 
unidentified fragments in MS-MS specter (fig. 42), it was suggested that the purified extract might 
contain at least two different kinds of phophocholine molecules. This might be possible to confirm, 
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but it is challenging due to the requirement of higher amount and higher purity of the sample to 
provide better MS and NMR spectra. 
Elucidation of the unknown side chain might be possible by using GC-MS. Because of the higher 
energy transfer during ionization compared to the LC-MS technique, GC-MS is capable to break 
carbon-carbon bonds, and hence detect differences in the carbon side chain. Due to a limited time 
perspective in this project, this was not performed at this stage. Moreover, since the results from the 
testing of the purified compound did not show any anti-inflammatory activity, it was logical to accept 
that the compound was no “hit” as a lead compound, and therefore further investigation was not 
carried out. 
On the other hand, the molecular formula generated by using ToF-MS resulted in several 
alternatives, and the inconsistency between the HR-MS and NMR data might be due to that the 
molecular formula, C30H51NO7P, was not the correct one. 
In testing of the purified compound, no activities could be detected at any concentrations. There are 
several reasons for why the activity could not be reproduced after purification. The active compound 
might be unstable in the selected conditions for the isolation process, leading to loss or reduction of 
the activities detected in primary screening and retesting. There is also the possibility that the 
activities were caused by other compounds than the purified compound. To confirm this, every 
compound present in the fraction need to be isolated and tested, which is too time-consuming and 
resource demanding to carry out in this project. The activity might also arise from a synergic effect 
from several compounds present in the fraction. Moreover, since the isolation of the compounds m/z 
341.2 and 345.1 could not be achieved, the possibility that it was these compounds that were 
bioactive could not be excluded. 
In this study only the gonads and intestine, collected the same day, were investigated for bioactivity. 
There is still a great amount of work that could be done, for instance looking at differences between 
male and female extracts, seasonal variation in extract composition and differences due to 
geographical location, diet, pollution and other environmental factors. There is also the possibility of 
screening other organs and tissues of Echinus esculentus, including the shell. Similarly for bryozoans, 
varying environmental factors and geographical locations may cause a difference in metabolite 
production between colonies. It has also been speculated that several natural products may not 
actually originate from bryozoans themselves, but from endosymbiotic microorganisms unique to 
bryozoans [41]. 
The results from bioactivity testing revealed the Echinus esculentus intestinal extract (M10027-2-L01) 
as an extract with high possibility of containing active compounds. However, the amount of the 
crude extract was too minuscule to attempt any further purification and characterization. In order to 
pursue the bioactive constituents, it is likely that a recollection of the organism will be needed in 
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order to have sufficient extract to purify. This will hopefully lead to sufficient quantities of purified 
bioactive compound(s) to permit subsequent characterization. On the other hand, the processes 
involved from the sample collection to structure elucidation are time-consuming and resource 
demanding. 
Although no novel scaffolds were characterized from Eucratea loricata and Echinus esculentus, this 
project has demonstrated the complete marine bioprospecting process as a starting point in the drug 
discovery process. Most of natural product screening is focusing on novel anticancer compounds. 
This project has contributed in amplifying the knowledge about screening of natural product with 
anti-inflammatory and immunostimulatory activities. In addition, this project provides background 
information about marine natural product research and current anti-inflammatory investigations of 
marine organisms. Furthermore, the project has also highlighted that marine organisms contain 
interesting substances, and that the marine environments still might be an important source for 
novel bioactive compounds. The present project is the first report on the isolation of 
phosphocholines from the sea urchin Echinus Esculentus, and hopefully, this work might also assist 






5 Conclusion and future perspective 
The aim of this project was to investigate extracts from the bryozoan Eucratea loricate and the sea 
urchin Echinus esculentus for anti-inflammatory and immunostimulatory activities, and if possible 
determine the molecular structure of the active compounds. A total of four extracts: M08004-0-W01 
(aqueous extract of the bryozoan), M08004-0-L01 (organic extract of the bryozoan), M10027-1-L01 
(organic extract of the sea urchin gonad), and M10027-2-L01 (organic extract of the sea urchin 
testines) were screened against NFκB, IL-1β and TNF-α. No significant immunostimulatory activities 
were detected in any of these extracts. The results from the anti-inflammatory screenings indicated 
that fraction 27 from both M10027-1 and M10027-2 extracts were active. Since the amount of the 
crude extract M10027-2 was not high enough to carry through the isolation and structure elucidation 
process, only fraction 27 of the extract M10027-1 was further investigated. After the dereplication, 
the molecule with 567.3 amu, with the elemental composition C30H50NO7P, was chosen to be the 
target compound. The results from structure elucidation of the molecule indicated that the target 
compound was a phosphocholine with an unknown side chain. Testing this target molecule for anti-
inflammatory activity revealed that it had no effect. Therefore it was concluded that the compound 
was not the active agent. 
The present project has shown that the sea urchin Echinus esculentus intestines contain bioactive 
constituents. Recollection of the organism is necessary in order to pursue any further investigation 
for bioactive constituents, and this might hopefully lead to the discovery of interesting compounds 
with anti-inflammatory activity. In addition, further isolation of the remaining compounds present in 
fraction 27 may hopefully provide active agents. Moreover, further investigation of the structure of 
the target compound may lead to the discovery of a new molecule. There are many important and 
useful results from the NMR and MS/MS analysis. Nevertheless, further structure elucidation will 
demand better purity of the compound for NMR analysis, while GC-MS is an option for elucidating 
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